Literature DB >> 25469278

Comparison of the diagnostic performance of 18F-fluorothymidine versus 18F-fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis.

Xiao-Feng Li1, Dong Dai1, Xiu-Yu Song1, Jian-Jing Liu1, Yan-Jia Zhu1, Wen-Gui Xu1.   

Abstract

A pulmonary lesion is an extremely common and clinically challenging disorder worldwide, and an accurate diagnosis of lung cancer is crucial for early treatment and management. The aim of the present study was to perform a comprehensive meta analysis to compare the diagnostic performance of 18F-fluorothymidine (18F-FLT) positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) PET in evaluating patients with pulmonary lesions. Relevant studies were identified using the PubMed, EMBASE and Cochrane library databases. The pooled estimated sensitivity, specificity, positive-likelihood ratio, negative-likelihood ratio, and diagnostic odds ratio (DOR) for 18F-FLT PET versus 18F-FDG PET were calculated as the main outcome measures. Summary receiver operating characteristic curves were also constructed by Meta-Disk 1.4 software using a Mose's constant of linear model. The meta analysis showed that 18F-FLT PET had a higher specificity (0.70; 95% CI, 0.61-0.77), but lower sensitivity (0.81; 95% CI, 0.74-0.87) compared to 18F-FDG PET (0.50; 95% CI, 0.41-0.58 for specificity; 0.92; 95% CI 0.86-0.95 for sensitivity). For DOR, 18F-FLT PET (12.58; 95% CI, 6.81-23.24) was higher compared to 18F-FDG PET (10.72; 95% CI, 5.51-20.87). The area under the curve was 0.8592 and 0.9240 for 18F-FLT PET and 18F-FDG PET, respectively (Z=0.976, P>0.05). In conclusion, 18F-FLT PET and 18F-FDG PET had good diagnostic performance for the overall assessment of pulmonary lesions, and 18F-FLT PET had a higher specificity compared to 18F-FDG PET, but was less sensitive than 18F-FDG PET. Therefore, 18F-FLT and 18F-FDG together could add diagnostic confidence for pulmonary lesions.

Entities:  

Keywords:  18F-fluorodeoxyglucose; 18F-fluorothymidine; meta analysis; positron emission tomography; pulmonary lesions

Year:  2014        PMID: 25469278      PMCID: PMC4251140          DOI: 10.3892/mco.2014.440

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  29 in total

1.  Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer.

Authors:  S P Changlai; S C Tsai; M C Chou; Y J Ho; C H Kao
Journal:  Oncol Rep       Date:  2001 Mar-Apr       Impact factor: 3.906

2.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

3.  ¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.

Authors:  Kyoichi Kaira; Nobuyuki Yamamoto; Masahiro Endo; Hirotsugu Kenmotsu; Tateaki Naito; Akira Ono; Haruyasu Murakami; Yasuhisa Ohde; Takashi Nakajima; Toshiaki Takahashi
Journal:  Oncol Rep       Date:  2013-10-24       Impact factor: 3.906

4.  Clinical relevance of imaging proliferative activity in lung nodules.

Authors:  Andreas K Buck; Martin Hetzel; Holger Schirrmeister; Gisela Halter; Peter Möller; Clemens Kratochwil; Andreas Wahl; Gerhard Glatting; Felix M Mottaghy; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-14       Impact factor: 9.236

5.  Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Authors:  Linda Mileshkin; Rodney J Hicks; Brett G M Hughes; Paul L R Mitchell; Veena Charu; Barbara J Gitlitz; David Macfarlane; Benjamin Solomon; Lukas C Amler; Wei Yu; Andrea Pirzkall; Bernard M Fine
Journal:  Clin Cancer Res       Date:  2011-03-01       Impact factor: 12.531

6.  Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions?

Authors:  Baixuan Xu; Zhiwei Guan; Changbin Liu; Ruimin Wang; Dayi Yin; Jinming Zhang; Yingmao Chen; Shulin Yao; Mingzhe Shao; Hui Wang; Jiahe Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10-09       Impact factor: 9.236

7.  Combined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study.

Authors:  Xiao-Feng Li; Tao Huang; Huijie Jiang; Xuemei Wang; Baozhong Shen; Xiangcheng Wang; Chin K Ng; Gregory C Postel; A Cahid Civelek
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 8.  Performance of whole-body PET/CT for the detection of distant malignancies in various cancers: a systematic review and meta-analysis.

Authors:  Guozeng Xu; Lin Zhao; Zhiyi He
Journal:  J Nucl Med       Date:  2012-10-16       Impact factor: 10.057

9.  A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.

Authors:  Jiahe Tian; Xiaofeng Yang; Lijuan Yu; Ping Chen; Jun Xin; Liming Ma; Huiru Feng; Yieyin Tan; Zhoushe Zhao; Wenkai Wu
Journal:  J Nucl Med       Date:  2008-01-16       Impact factor: 10.057

10.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.

Authors:  Andreas K Buck; Holger Schirrmeister; Martin Hetzel; Mareike Von Der Heide; Gisela Halter; Gerhard Glatting; Torsten Mattfeldt; Florian Liewald; Sven N Reske; Bernd Neumaier
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  7 in total

1.  Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy.

Authors:  John A Cieslak; Zita A Sibenaller; Susan A Walsh; Laura L Boles Ponto; Juan Du; John J Sunderland; Joseph J Cullen
Journal:  Radiat Res       Date:  2015-12-31       Impact factor: 2.841

2.  Solitary pulmonary nodule imaging approaches and the role of optical fibre-based technologies.

Authors:  Susan Fernandes; Gareth Williams; Elvira Williams; Katjana Ehrlich; James Stone; Neil Finlayson; Mark Bradley; Robert R Thomson; Ahsan R Akram; Kevin Dhaliwal
Journal:  Eur Respir J       Date:  2021-03-25       Impact factor: 16.671

3.  Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis.

Authors:  G M Kramer; Y Liu; A J de Langen; E P Jansma; I Trigonis; M-C Asselin; A Jackson; L Kenny; E O Aboagye; O S Hoekstra; R Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-23       Impact factor: 9.236

4.  Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer.

Authors:  Kalevi Kairemo; Elmer B Santos; Homer A Macapinlac; Vivek Subbiah
Journal:  Diagnostics (Basel)       Date:  2020-01-06

Review 5.  Diagnostic Performance of PET or PET/CT with Different Radiotracers in Patients with Suspicious Lung Cancer or Pleural Tumours according to Published Meta-Analyses.

Authors:  Filippo Lococo; Barbara Muoio; Marco Chiappetta; Dania Nachira; Leonardo Petracca Ciavarella; Stefano Margaritora; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2020-04-25       Impact factor: 3.161

6.  Alternative and New Radiopharmaceutical Agents for Lung Cancer.

Authors:  Silvi Telo; Letizia Calderoni; Sara Vichi; Federico Zagni; Paolo Castellucci; Stefano Fanti
Journal:  Curr Radiopharm       Date:  2020

7.  Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.

Authors:  Fanxiao Liu; Qingyu Zhang; Dezhi Zhu; Fengxia Liu; Zhenfeng Li; Jianmin Li; Bomin Wang; Dongsheng Zhou; Jinlei Dong
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.